Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272

Print Friendly, PDF & Email

Second Generation Mitochondrial Targeted Candidate Enters Clinic with Potential to Treat Neurodegenerative Diseases BOSTON, Jan. 21, 2020 /PRNewswire/ — Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the initiation of a first-in-human […]